Ono Pharmaceutical (OTCMKTS:OPHLF) Announces Earnings Results

Ono Pharmaceutical (OTCMKTS:OPHLF) announced its earnings results on Monday. The company reported $0.21 earnings per share (EPS) for the quarter, Zacks reports. Ono Pharmaceutical had a return on equity of 11.85% and a net margin of 19.64%.

Ono Pharmaceutical Price Performance

OPHLF stock opened at $10.18 on Wednesday. The stock’s 50 day moving average is $10.33 and its two-hundred day moving average is $12.46. Ono Pharmaceutical has a 52-week low of $9.22 and a 52-week high of $16.82. The company has a market capitalization of $4.78 billion, a PE ratio of 6.88 and a beta of 0.59. The company has a quick ratio of 2.80, a current ratio of 3.22 and a debt-to-equity ratio of 0.15.

About Ono Pharmaceutical

Ono Pharmaceutical Co, Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia.